How, if at all, has the FDA approval of zidesamtinib changed your treatment approach for patients with locally advanced or metastatic ROS1+ NSCLC who have previously received a ROS1 kinase inhibitor?

The availability of zidesamtinib gives patients with ROS1+ NSCLC an important option after prior ROS1 TKI therapy. The overall efficacy is encouraging: RR after prior ROS1 TKI was 44%, median duration not yet reached but 62% were ongoing at 18 months. If the prior TKI was an older generation (crizot...